公开(公告)号：AU2008353452A1

公开(公告)日：2009-10-01

申请号：AU2008353452

申请日：2008-05-29

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  HSIEH SHIE-LIANG ,  CHEN SZU-TING ,  HSU TSUI-LING

IPC: G01N33/53

Abstract: Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flavivirus, binds via glycan binding are determined. Once the receptors are determined, the effect of binding to a particular receptor may be determined, wherein targeting of the receptors causing a particular symptom may be targeted by agents that interrupt binding of the pathogen to the receptor. Accordingly, in the case of dengue virus and Japanese encephamyelitis virus, TNF-alpha is released when the pathogen binds to the DLVR1/CLEC5A receptor. Interrupting the DLVR1/CLEC5A receptor with monoclonal antibodies reduced TNF-alpha secretion without affecting secretion of cytokines responsible for viral clearance thereby increasing survival rates in infected mice from nil to around 50%.

公开(公告)号：GB2458715A

公开(公告)日：2009-09-30

申请号：GB0812915

申请日：2008-07-15

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  HSIEH SHIE-LIANG ,  HSU TSUI-LING ,  CHEN SZU-TING

IPC: A61K39/395 ,  C07K16/28

Abstract: A pharmaceutical composition is disclosed comprising an effective amount of an antibody directed against at least one cellular receptor to modulate the effects of a pathogen infection, wherein the modulation comprises at least inhibition of pro-inflammatory cytokine secretion and does not affect secretion of cytokines that affect viral clearance. The cellular receptor may be the DLVR1 / CLEC5A (DVLR1, MDL-1) receptor. The pathogen may be a hepatitis virus or a flavivirus (e.g. Japanese encephalomyelitis virus or dengue virus). Use of an anti-DLVR1/CLEC5A antibody in the treatment of a flavivirus infection is claimed. A method comprising obtaining a fusion protein comprising a binding domain of a DLVR1/CLEC5A receptor and a domain that allows affixing to a substrate, contacting the fusion protein with a flavivirus to determine if the pathogen binds to the binding domain of the fusion, and detecting whether the pathogen is bound to the fusion protein, is also claimed.

公开(公告)号：IL194993D0

公开(公告)日：2009-08-03

申请号：IL19499308

申请日：2008-10-30

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC OF

IPC: C12Q20100101

Abstract: This invention relates to predicting a patient's warfarin dose based on the nucleotide at position -1639 of the VKORC1 gene and the genotype of the CYP2C9 gene in that patient. The warfarin dose so predicted can be further adjusted according to the patient's non-genetic factors, e.g., age, body surface area, medical conditions, and use or non-use of certain drugs.

公开(公告)号：GB0812915D0

公开(公告)日：2008-08-20

申请号：GB0812915

申请日：2008-07-15

Applicant: ACADEMIA SINICA

Abstract: Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flavivirus, binds via glycan binding are determined. Once the receptors are determined, the effect of binding to a particular receptor may be determined, wherein targeting of the receptors causing a particular symptom may be targeted by agents that interrupt binding of the pathogen to the receptor. Accordingly, in the case of dengue virus and Japanese encephamyelitis virus, TNF-alpha is released when the pathogen binds to the DLVR1/CLEC5A receptor. Interrupting the DLVR1/CLEC5A receptor with monoclonal antibodies reduced TNF-alpha secretion without affecting secretion of cytokines responsible for viral clearance thereby increasing survival rates in infected mice from nil to around 50%.

公开(公告)号：AU2005319028A1

公开(公告)日：2006-06-29

申请号：AU2005319028

申请日：2005-12-21

Applicant: ACADEMIA SINICA

Inventor： CHENG YAUN-TSONG ,  CHEN JIN-JER ,  YUAN HSIANG-YU

IPC: C12Q1/68

Abstract: We discovered that a polymorphism in the promoter of the VKORCI gene is associated with warfarin sensitivity. This polymorphism can explain both the interindividual and inter-ethnic differences in warfarin dose requirements. Furthermore, the polymorphism is also associated with promoter activity. Thus, the promoter sequence or activity of the VKORCI gene of a subject can be used to predict how much warfarin should be prescribed for the subject. Relevant methods and compositions are provided.

公开(公告)号：AU2004289951A1

公开(公告)日：2005-05-26

申请号：AU2004289951

申请日：2004-06-18

Applicant: ACADEMIA SINICA

Inventor： CHUNG WEN-HUNG ,  CHEN YUAN-TSONG ,  HUNG SHUEN-IU ,  WU JER-YUARN

IPC: C12Q1/68 ,  G01N33/94

公开(公告)号：NZ519789A

公开(公告)日：2004-04-30

申请号：NZ51978902

申请日：2002-06-25

Applicant: UNIV NAT TAIWAN ,  ACADEMIA SINICA ,  NAT HEALTH RESEARCH INSTITUTES

Inventor： CHEN JEREMY J W ,  YANG SHUENN-CHEN ,  YANG PAN-CHYR ,  PECK KONAN ,  WU CHENG-WEN ,  SHIH JIN-YUAN ,  HONG TSE-MING

IPC: G01N33/50 ,  C12N15/09 ,  C12Q1/68 ,  C12Q1/6886 ,  G01N33/15 ,  G01N33/574 ,  G01N37/00 ,  A61B5/00

Abstract: A method for determining the tumor invasive or metastatic potential of a sample, comprising a) determining the abundance in the sample of a nucleic acid selected from group I or II; b) determining the abundance in a second sample of same nucleic acid; c) comparing the two results; d) categorizing the sample as having tumor invasive or metastatic potential based on the results of (c).

公开(公告)号：DE69912058T2

公开(公告)日：2004-04-29

申请号：DE69912058

申请日：1999-04-28

Applicant: ACADEMIA SINICA TAIPEH T AI PE

Inventor： ROFFLER STEVE ,  CHERN JI-WANG ,  LEU YE-LIN

IPC: C07D491/04 ,  C07H15/26 ,  C07H15/203 ,  C07D491/22 ,  A61K31/70

Abstract: The present invention features proactive antitumor compounds of the following formula: wherein R is COOZ; Z being H, alkali metal, alkaline earth metal, an ammonium group which is optionally substituted with one or more alkyl groups, or a carboxyl protecting group; each of R , R , and R , independently, is OH or OR ; R being a hydroxyl protecting group; X is benzene or pyridine, optionally substituted with R ; R being H, C1-5 alkyl, C1-5 alkoxy, NO2, F, Cl, Br, SO3H, and CN; R is H or OH; and each of n and m, independently, is 0 or 1; or a salt thereof.

公开(公告)号：NO20040966A

公开(公告)日：2004-04-22

申请号：NO20040966

申请日：2004-03-05

Applicant: ACADEMIA SINICA

Inventor： HUEY-LANG YANG ,  YU JAMES CHEIN-CHIH ,  LIN JOHN HAN-YOU

IPC: A61K39/00 ,  A01N63/00 ,  A61K39/02 ,  A61K39/104 ,  A61K47/00 ,  A61P31/04 ,  C12N15/09 ,  C12N15/63

CPC classification number: A61K39/104 ,  A61K2039/52 ,  A61K2039/53 ,  A61K2039/542

公开(公告)号：AU5063402A

公开(公告)日：2003-10-30

申请号：AU5063402

申请日：2002-06-26

Applicant: UNIV NAT TAIWAN ,  NAT HEALTH RESEARCH INSTITUTES ,  ACADEMIA SINICA

Inventor： CHEN JEREMY J W ,  WU CHENG-WEN ,  YANG SHUENN-CHEN ,  HONG TSE-MING ,  PECK KONAN ,  YANG PAN-CHYR

IPC: G01N33/50 ,  C12N15/09 ,  C12Q1/68 ,  C12Q1/6886 ,  G01N33/15 ,  G01N33/574 ,  G01N37/00

Abstract: Many genes are identified as being metastasis associated. Identifying and profiling of these genes expression can be used to evaluate a sample, to diagnose tumor invasive potential or metastatic development in a sample, or screen for a test compound useful in the prevention or treatment of tumor metastasis.